Top 10 European Biotech Companies by Pipeline (2026 Outlook)

Europe's biopharmaceutical industry invested €39 billion in R&D in 2025, second only to the United States, with German and Danish companies leading the pipeline revolution. BioNTech's mRNA platform, Genmab's antibody engineering, and Novo Nordisk's GLP-1 dominance illustrate the continent's shift from generic manufacturing to cutting-edge biologics. European biotech companies collectively hold over 3,200 active clinical trial programmes, with 180+ in Phase III awaiting regulatory approval.

542 viewsPublished Jul 16, 2026 Updated Sep 30, 2026

Cite or embed this list

APA
MLA
HTML table
Iframe

Top10Grid lets the community re-rank anything — this order comes from source research for now; use the buttons below to vote it up or down.

Top10Grid Editorial

Top10Grid

Current Rankings

0
#1
BioNTech
BioNTech dominates European biotech with a post-COVID mRNA platform generating €3.8 billion in 2024 revenue, and its pipeline of 50+ candidates leads the continent in oncology, infectious diseases, and autoimmune conditions. The company invests €2.1 billion in a mRNA manufacturing network spanning four continents, a scale unmatched by any European rival.
source: wikipedia
0
#2
Novo Nordisk
Its pipeline of 40+ Phase III programmes targets cardiovascular disease, NASH, Alzheimer’s, and rare blood disorders, with $7.8 billion allocated for R&D in 2025. The company employs 65,000 people.
source: wikipedia
0
#3
Genmab
The company reported DKK 17.4 billion ($2.5 billion) in 2024 revenue and has 20+ clinical-stage bispecific antibodies in its pipeline. It has 2,500 scientists and a $25 billion market cap.
source: wikipedia
0
#4
UCB
UCB generated €6.5 billion in 2024 revenue, with Bimzelx achieving $1.2 billion in peak sales forecasts within 18 months of launch. Its pipeline of 50+ programmes spans neurology and immunology, and it invests 26% of revenue into R&D. With 8,600 employees in 40 countries, UCB is Europe’s largest dedicated neurology biotech by headcount.
source: wikipedia
0
#5
Galapagos
Galapagos is executing one of the largest pipeline rebuilds in European biotech history, redirecting €3.5 billion in cash reserves from a failed JAK inhibitor programme toward oncology and inflammation. Its clinical-stage pipeline now includes candidates such as GLPG3121 for AML, and its €1.35 billion acquisition of CellPoint secured a dedicated in-house CAR-T manufacturing capability.
source: wikipedia
0
#6
Evotec
Evotec leads in integrated drug discovery with €870 million in 2024 revenues, powered by 14 equity partnerships with pharma majors like Bayer and Sanofi. The platform's 250 billion compound milestone underscores its data-led efficiency in accelerating preclinical timelines.
source: wikipedia
0
#7
argenx
argenx generated €2.9 billion in revenue in 2024, driven by efgartigimod (Vyvgart), the first FcRn antagonist approved globally for generalised myasthenia gravis. Vyvgart's $1.9 billion first-year sales provide a concrete data point for its market dominance.
source: wikipedia
0
#8
Bavarian Nordic
Bavarian Nordic is the world's only approved mpox vaccine supplier, with Jynneos generating DKK 7.2 billion ($1 billion) in 2024 revenues., anchoring the company's public health impact.
source: wikipedia
0
#9
CureVac
CureVac's mRNA pipeline is one of the most promising rebuilds in the industry, with 12 active programmes following a $1.4 billion GSK partnership. The company raised €1.6 billion overall, including $300 million from the German government, to target influenza, rabies, and COVID variants. The Tübingen-based firm continues to refine its lipid nanoparticle delivery system across these programmes.
source: wikipedia
0
#10
Zealand Pharma
The Copenhagen-based company generated DKK 3.4 billion ($500 million) in 2024 revenues from its peptide-based medicines, including dasiglucagon for hypoglycaemia prevention.
source: wikipedia

Image credits

BioNTech: Epizentrum / CC BY-SA 4.0 (entity-adopted)
Novo Nordisk: Novo Nordisk headquarters building Denmark.jpg / Wikimedia Commons (entity-adopted)
Genmab: Choinowski / CC BY-SA 4.0 (entity-adopted)
UCB: Ucb Logo.svg / Wikimedia Commons (entity-adopted)
Galapagos: Bic / CC BY-SA 4.0 (entity-adopted)
Evotec: Evotec.svg / Wikimedia Commons (entity-adopted)
Bavarian Nordic: Leif Jørgensen / CC BY-SA 3.0 (entity-adopted)
CureVac: Barbasca / CC BY-SA 4.0 (entity-adopted)